Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived Wharton's jelly mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Shiraz University of Medical Sciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary
01
Overview
Umbilical cord-derived Wharton's jelly mesenchymal stem cells (WJ-MSCs) are multipotent stem cells isolated from the mucoid connective tissue of the umbilical cord. Developed by the Shiraz University of Medical Sciences, these cells are being evaluated in a Phase III clinical trial for the prevention of heart failure in patients who have suffered an acute myocardial infarction (AMI) with impaired left ventricular function. The therapeutic rationale is based on the cells' ability to migrate to injured tissues and exert cardioprotective effects through paracrine signaling, immunomodulation, and the promotion of angiogenesis. By secreting various growth factors and cytokines, WJ-MSCs help reduce inflammation, limit adverse ventricular remodeling, and potentially stimulate endogenous repair of the infarcted myocardium. In clinical settings, they are typically administered via intracoronary infusion shortly after primary percutaneous coronary intervention.
- Other names
- Wharton's jelly mesenchymal stem cellsumbilical cord-derived mesenchymal stem cellsUC-MSCs
Beyond the preview
Go deeper on umbilical cord-derived Wharton's jelly mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived Wharton's jelly mesenchymal stem cells.